INDEMNIFICATION AND ADVANCEMENT AGREEMENTIndemnification and Advancement Agreement • January 28th, 2021 • Sana Biotechnology, Inc. • Biological products, (no disgnostic substances) • Delaware
This Indemnification and Advancement Agreement (“Agreement”) is made as of ________ __, 20__ by and between Sana Biotechnology, Inc., a Delaware corporation (the “Company”), and ______________, [a member of the Board of Directors/an officer/an employee] of the Company (“Indemnitee”). This Agreement supersedes and replaces any and all previous Agreements between the Company and Indemnitee covering indemnification and advancement.
AMENDMENT NO. 4 TO EXCLUSIVE START-UP LICENSE AGREEMENT BETWEEN SANA BIOTECHNOLOGY, INC. AND UNIVERSITY OF WASHINGTONOriginal Agreement • January 28th, 2021 • Sana Biotechnology, Inc. • Biological products, (no disgnostic substances)
THIS AMENDMENT NO. 4 (“Amendment No. 4”), with an effective date of January 21, 2021 (“Amendment No. 4 Effective Date”), is entered into by and between Sana Biotechnology, Inc. (“Company”) and University of Washington (“University”).
AMENDMENT NO. 2 TO EXCLUSIVE START-UP LICENSE AGREEMENT BETWEEN CYTOCARDIA, INC. AND UNIVERSITY OF WASHINGTONOriginal Agreement • January 28th, 2021 • Sana Biotechnology, Inc. • Biological products, (no disgnostic substances)
THIS AMENDMENT NO. 2 (“Amendment No. 2”), with an effective date of July 16, 2020 (“Amendment No. 2 Effective Date”), is entered into by and between Cytocardia, Inc. (“Company”) and University of Washington (“University”).
